Reprogramming T cells as an emerging treatment to slow human age-related decline in health

[1]  Zev A. Binder,et al.  Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. , 2024, Nature medicine.

[2]  D. Tuveson,et al.  Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction , 2024, Nature aging.

[3]  Ilias Pessach,et al.  Leukapheresis for CAR-T cell production and therapy. , 2023, Transfusion and Apheresis Science.

[4]  F. Yang,et al.  Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors , 2023, Science China. Life sciences.

[5]  A. Nagler,et al.  Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma , 2023, Leukemia & lymphoma.

[6]  F. Anwer,et al.  Ethical Challenges in CAR-T slot allocation. , 2023, Transplantation and cellular therapy.

[7]  K. Huffman,et al.  Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial , 2023, Nature Aging.

[8]  N. Raje,et al.  Ethical challenges with multiple myeloma BCMA CAR-T slot allocation: a multi-institution experience. , 2023, Transplantation and cellular therapy.

[9]  R. Sobecks,et al.  P-007: Proposed clinical factors scoring system for chimeric antigen receptor T-cell (CAR T) patient selection in relapsed and refractory multiple myeloma (RRMM) , 2022, Clinical Lymphoma, Myeloma & Leukemia.

[10]  M. Ahmadi,et al.  CAR Treg: A new approach in the treatment of autoimmune diseases. , 2021, International immunopharmacology.

[11]  H. Heslop,et al.  Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. , 2021, Blood cancer discovery.

[12]  J. Lachaine,et al.  PCN191 Cost Associated with Implementation of CAR T-Cell Therapy for the Management of Hematologic Cancers in Canada. , 2021 .

[13]  Analiz Rodriguez,et al.  CAR T Cell Therapy for Pediatric Brain Tumors , 2020, Frontiers in Oncology.

[14]  Yu Cao,et al.  Engineered T Cell Therapy for Cancer in the Clinic , 2019, Front. Immunol..

[15]  Wei Hu,et al.  Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  M. Sadelain,et al.  Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells , 2019, Clinical Cancer Research.

[17]  Juanjuan Zhao,et al.  Universal CARs, universal T cells, and universal CAR T cells , 2018, Journal of Hematology & Oncology.

[18]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[19]  G. Hansen,et al.  Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma , 2017, Front. Immunol..

[20]  D. Scott,et al.  FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. , 2017, Blood.

[21]  A. Zhang,et al.  Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol , 2016, BMJ Open.

[22]  Carl H. June,et al.  Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition , 2016, Clinical Cancer Research.

[23]  R. Liblau,et al.  An antigen-specific pathway for CD8 T cells across the blood-brain barrier , 2007, The Journal of experimental medicine.